Gilead Sciences stock: 85.6% stayed on lenacapavir PrEP
Published on 11/11/2026 at 14:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLenacapavir data sharpen Gilead focus
- PURPOSE 5 showed materially stronger one-year PrEP persistence for twice-yearly lenacapavir than for daily oral F/TDF.
- No HIV acquisition occurred in the lenacapavir group during the 52-week study period.
- The HIV Glasgow presentation is the next catalyst for Gilead's long-acting prevention strategy.
Gilead Sciences stock traded at 152.68 euros on Lang & Schwarz at 14:17 CET on Wednesday, November 11, 2026, 1.05 percent above the Xetra close of Tuesday, November 10. The move came as investors assessed new evidence for the company's long-acting HIV prevention strategy.
In a release dated November 6, Gilead said its Phase 2 PURPOSE 5 trial showed significantly higher persistence with twice-yearly injectable lenacapavir than with daily oral emtricitabine/tenofovir disoproxil fumarate, or F/TDF. The company defines persistence as consistent and continuous on-time use. The findings are being presented at HIV Glasgow 2026.
Persistence is the central signal
At Week 52, 85.6 percent of participants receiving lenacapavir remained persistent on PrEP, compared with 46.3 percent in the F/TDF group. The difference was 39.3 percentage points and was statistically significant at p<0.0001, according to Gilead Sciences.
The randomized, open-label study enrolled 267 people in the United Kingdom and France who were not taking PrEP at enrollment. Participants were assigned in a 2:1 ratio to twice-yearly lenacapavir or daily F/TDF and followed for 52 weeks. Among the participants included in the Week 52 analysis, 154 of 180 in the lenacapavir group and 37 of 80 in the F/TDF group met the persistence definition.
No HIV acquisition occurred among participants receiving lenacapavir during the study period. One acquisition occurred in the F/TDF group, with drug-level analysis consistent with fewer than two doses per week at diagnosis. Serious adverse events were uncommon and occurred in 3.9 percent of participants receiving lenacapavir and 3.4 percent receiving F/TDF; investigators found none related to study treatment.
Commercial promise still needs execution
The data strengthen the case that less frequent dosing could help address adherence challenges that limit the real-world effectiveness of daily PrEP. For Gilead, the result supports the broader PURPOSE development program and gives the company a further clinical argument for long-acting prevention.
That does not by itself establish future sales. Uptake will depend on regulatory conditions, access, pricing, clinical practice and the durability of the safety profile. Injection-site reactions were common in the study, although the company described the overall safety profile as consistent with previous lenacapavir studies.
Gilead Sciences market snapshot
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Lang & Schwarz price: 152.68 euros at 14:17 CET on November 11, 2026
- Daily comparison: 1.05 percent above the Xetra close of 151.10 euros on November 10, 2026
- Study: Phase 2 PURPOSE 5
The broader market setting remains relevant for biotechnology valuations; investors can follow the S&P 500 market environment.
The next catalyst is the HIV Glasgow presentation of the PURPOSE 5 findings, which will test how the clinical results are received by researchers and investors. More news and analyses on Gilead Sciences stock.
